You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com |
|
Most viewed
- 1. Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies, Published in Journal of Hematology & Oncology
- 2. Prognostic analysis and association of the systemic immune-inflammatory index with immune checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer
- 3. Hyperprogression disease induced by Sintilimab combined with Oxaliplatin and S-1 after surgery: a case report and literature review
- 4. BioNTech buys mRNA, courtroom rival CureVac in all-stock deal
- 5. Exploring a new direction in targeted cancer therapy through hyperbaric oxygen therapy combined with biomedical engineering techniques
- 6. Proton beam therapy for a patient with prostatic rhabdomyosarcoma: a case report and review of the literature
- 7. Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties
- 8. Management of multiple primary prostate malignant tumors: case report of synchronous prostatic adenocarcinoma and lymphoma
- 9. The glucocorticoid receptor is a double-edged sword in prostate cancer
- 10. A study led by CIC bioGUNE delves into the complexity of the most aggressive form of prostate cancer
Last updated at 18:39 GMT
Hot News Makers
Health/Pharma Companies
-
148363.15
-
36323.51
-
15329.40
-
13679.23
-
10818.57
-
8712.36
-
7428.70
-
6785.56
-
6148.05
-
6107.01
Drugs, Treatments, Trials
-
22042.25
-
8655.59
-
4928.13
-
4545.34
-
3099.83
-
1562.35
-
981.78
-
652.25
-
617.71
-
555.94
Last updated at 18:10 GMT
